# Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury

> **NCT04595916** · PHASE4 · COMPLETED · sponsor: **Sichuan Haisco Pharmaceutical Group Co., Ltd** · enrollment: 73 (actual)

## Conditions studied

- Acute Drug Induced Liver Injury

## Interventions

- **DRUG:** Polyene phosphatidylcholine injection 930 mg QD
- **DRUG:** Magnesium Isoglycyrrhizinate injection 200 mg QD

## Key facts

- **NCT ID:** NCT04595916
- **Lead sponsor:** Sichuan Haisco Pharmaceutical Group Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-04
- **Primary completion:** 2020-10-21
- **Final completion:** 2020-11-02
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2020-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04595916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04595916, "Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04595916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*